We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
- Authors
Mortenson, Melinda M; Schlieman, Michael G; Virudachalam, Subbulakshmi; Bold, Richard J
- Abstract
Non-small-cell lung cancer (NSCLC) has a poor prognosis. Despite advances in therapy, survival has improved only slightly. The 26S proteasome regulates multiple cellular processes through degradation of ubiquitin-tagged proteins. The proteasome inhibitor, bortezomib (Velcade, formerly PS-341), has been shown to be an active anticancer agent both in vitro and in vivo in multiple tumor types.
- Publication
Cancer chemotherapy and pharmacology, 2004, Vol 54, Issue 4, p343
- ISSN
0344-5704
- Publication type
Journal Article
- DOI
10.1007/s00280-004-0811-4